Plum to buy 100.00% interest in Ip

original title: Announcement of the follow-up progress of Meihua Biotech Group Co., Ltdon matters related to the issuance of shares to purchase assets
eNuSecurities Code: 600873 Securities: Plum Bio Announcement No2015-034eNuEmeiFlower Biotech Group Co., Ltdon the subsequent progress of theeNuissued shares to purchase assets
eNu
Meihua Biotech Group Co., Ltd(hereinafter referred to as Meihua Bio or Company) intends to issue shares to nine enterprises, including Tie Xiaorong and Ningxia Yipin Investment Group Co., Ltd., and pay 70,000 yuan in cash to purchase 100.00% interest in Ningxia Yipin Biotech Co., Ltd(hereinafter referred to as Yipin Biotech)The matter has been considered and approved by the 11th meeting of the Company's 7th Board of Directors and the first interim general meeting in 2015 eNu
　　In accordance with the relevant provisions of the Anti-monopoly Law of the People's Republic of China and the Measures for the Centralization of Business Operators, Meihua Bio, as a declaration obligor, has submitted to the Ministry of Commerce the relevant materials for centralized examination by the operators eNu
　　On March 5, 2015, the Company received Notice No 53 of the Antimonopoly Bureau of the Ministry of Commerce (2015): In accordance with Article 21 of the Anti-Monopoly Law of the People's Republic of China and Article 14 of the Measures for the Centralization of Business Operators, it has decided to file a case and enter the review stage of the acquisition of 100% of the shares of Eppin Bio (specifically disclosed on the Shanghai Stock Exchange website on March 6, 2015) eNu
　　Today, the Company received the Notice of Implementation of Further Review issued by the Antimonopoly Bureau of the Ministry of Commerce (Commercial Anti-Graft Letter of First Instance, No 69): In accordance with Article 25 of the Anti-Monopoly Law of the People's Republic of China, after preliminary examination, it is now decided to conduct further review of the case concerning the acquisition of 100% equity of Ningxia Yipin Biotech Co., Ltd by Meihua Biotech Group Co., Ltd eNu
　　The matters related to the issuance of shares to purchase assets and raise supporting funds by the Company shall be implemented only after the approval of the CSRC and the central examination and approval of the operators of the transaction by the Ministry of Commerce eNu
　　The board of directors of the company reminds investors to invest rationally and pay attention to investment risks The Company designated the information disclosure media as the Shanghai Securities News, Shanghai Stock Exchange website ( the company will strictly in accordance with the relevant laws, regulations and requirements, timely information disclosure work eNu
　　This announcement is hereby made eNu
eNu Board of Directors of Meihua Biotech Group Co., Ltd eNu , April 3, 2015, with the original title: "The follow-up progress announcement of Meihua Biotech Group Co., Ltd on matters related to the issuance of shares to purchase assets
eNu Securities Code: 600873 Securities Short: Plum Bio Announcement No: 2015 -034 eNu Meihua Biotech Group Co., Ltd on the eNu issued shares to purchase assets related matters follow-up announcement eNu the board of directors and all directors of this notice to ensure that there are no false records, misleading statements or material omissions, and to bear individual and joint liability for the authenticity, accuracy and completeness of its contents eNu
　　Meihua Biotech Group Co., Ltd (hereinafter referred to as Meihua Bio or Company) intends to issue shares to nine enterprises, including Tie Xiaorong and Ningxia Yipin Investment Group Co., Ltd., and pay 70,000 yuan in cash to purchase 100.00% interest in Ningxia Yipin Biotech Co., Ltd (hereinafter referred to as Yipin Biotech) The matter has been considered and approved by the 11th meeting of the Company's 7th Board of Directors and the first interim general meeting in 2015 eNu
　　In accordance with the relevant provisions of the Anti-monopoly Law of the People's Republic of China and the Measures for the Centralization of Business Operators, Meihua Bio, as a declaration obligor, has submitted to the Ministry of Commerce the relevant materials for centralized examination by the operators eNu
　　On March 5, 2015, the Company received Notice No 53 of the Antimonopoly Bureau of the Ministry of Commerce (2015): In accordance with Article 21 of the Anti-Monopoly Law of the People's Republic of China and Article 14 of the Measures for the Centralization of Business Operators, it has decided to file a case and enter the review stage of the acquisition of 100% of the shares of Eppin Bio (specifically disclosed on the Shanghai Stock Exchange website on March 6, 2015) eNu
　　Today, the Company received the Notice of Implementation of Further Review issued by the Antimonopoly Bureau of the Ministry of Commerce (Commercial Anti-Graft Letter of First Instance, No 69): In accordance with Article 25 of the Anti-Monopoly Law of the People's Republic of China, after preliminary examination, it is now decided to conduct further review of the case concerning the acquisition of 100% equity of Ningxia Yipin Biotech Co., Ltd by Meihua Biotech Group Co., Ltd eNu
　　The matters related to the issuance of shares to purchase assets and raise supporting funds by the Company shall be implemented only after the approval of the CSRC and the central examination and approval of the operators of the transaction by the Ministry of Commerce eNu
　　The board of directors of the company reminds investors to invest rationally and pay attention to investment risks The Company designated the information disclosure media as the Shanghai Securities News, Shanghai Stock Exchange website ( the company will strictly in accordance with the relevant laws, regulations and requirements, timely information disclosure work eNu
　　This announcement is hereby made eNu
eNu , Board of Directors of Meihua Biotech Group Co., Ltd., shared this feed tweet on April 3, 2015 eNu